

# ASX release

27 September 2022

## Change of Director's Interest – David Koczkar

In accordance with the Listing Rules, Medibank attaches an Appendix 3Y – Change of Director's Interest Notice for David Koczkar for release to the market.

This document has been authorised for release by Mei Ramsay, Company Secretary.

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

|  |
|--|
| Name of entity: MEDIBANK PRIVATE LIMITED |
| ABN: 47 080 890 259                      |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                     |                  |
|---------------------|------------------|
| Name of Director    | David Koczkar    |
| Date of last notice | 7 September 2022 |

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |  |
|---|--|
| Direct or indirect interest   | Direct (Performance Rights pursuant to the Medibank Private Limited Performance Rights Plan ('Performance Rights Plan'))   |
| Nature of indirect interest<br>(including registered holder)<br><small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> |  |
| Date of change  | 19 September 2022  |
| No. of securities held prior to change  | 1,028,258 Performance Rights, being: <ul style="list-style-type: none"><li>• 102,787 Performance Rights granted under the FY21 Deferred Short Term Incentive (<i>Deferred STI</i>);</li><li>• 206,622 Performance Rights granted under the FY21 Long Term Incentive (<i>LTI</i>); and</li><li>• 718,849 Performance Rights granted under the FY22 LTI.</li></ul> |
| Class   | Performance Rights   |
| Number acquired   | Nil  |

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

|   |   |
|---|---|
| Number disposed   | 102,787 Performance Rights vested and converted to ordinary shares in Medibank Private Limited ( <i>Ordinary Shares</i> ) as set out below.   |
| Value/Consideration<br><small>Note: If consideration is non-cash, provide details and estimated valuation</small>   | Performance Rights granted at nil consideration under the terms of the Performance Rights Plan.   |
| No. of securities held after change   | 925,471 Performance Rights, being: <ul style="list-style-type: none"> <li>• 206,622 Performance Rights granted under the FY21 LTI; and</li> <li>• 718,849 Performance Rights granted under the FY22 LTI.</li> </ul> |
| Nature of change<br><small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small> | Vesting of Performance Rights under the Performance Rights Plan   |

|  |  |
|--|--|
| Direct or indirect interest  | Direct and Indirect  |
| Nature of indirect interest (including registered holder)<br><small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | Indirect interest in Ordinary Shares held via Olive Man Investments Pty Ltd  |
| Date of change   | 19 September 2022  |
| No. of securities held prior to change   | 933,759 Ordinary Shares, being: <ul style="list-style-type: none"> <li>• 75,025 Ordinary Shares (direct); and</li> <li>• 858,734 Ordinary Shares (indirect).</li> </ul>  |
| Class  | Ordinary Shares  |
| Number acquired  | 108,838 Ordinary Shares (direct), being: <ul style="list-style-type: none"> <li>• 102,787 Ordinary Shares following vesting of 102,787 Performance Rights granted under the FY21 Deferred STI; and</li> <li>• 6,051 Ordinary Shares, being the number of Ordinary Shares having an equivalent value to the dividends that would have been received during the deferral period if Ordinary Shares were held instead of the Performance Rights granted under the FY21 Deferred STI.</li> </ul> |
| Number disposed  | Nil  |
| Value/Consideration<br><small>Note: If consideration is non-cash, provide details and estimated valuation</small>  | Acquisition of Ordinary Shares pursuant to vesting of Performance Rights under the Performance Rights Plan for no consideration.   |

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

|  |  |
|--|--|
| No. of securities held after change  | 1,042,597 Ordinary Shares, being: <ul style="list-style-type: none"> <li>• 183,863 Ordinary Shares (direct); and</li> <li>• 858,734 Ordinary Shares (indirect).</li> </ul> |
| <b>Nature of change</b><br><small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small> | Acquisition of Ordinary Shares pursuant to vesting of Performance Rights under and in accordance with the terms of the Performance Rights Plan.                            |

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |     |
|---|-----|
| Detail of contract  | N/A |
| Nature of interest  | N/A |
| Name of registered holder (if issued securities)  | N/A |
| Date of change  | N/A |
| <b>No. and class of securities to which interest related prior to change</b><br><small>Note: Details are only required for a contract in relation to which the interest has changed</small> | N/A |
| Interest acquired   | N/A |
| Interest disposed   | N/A |
| <b>Value/Consideration</b><br><small>Note: If consideration is non-cash, provide details and an estimated valuation</small>   | N/A |
| Interest after change   | N/A |

## Part 3 – <sup>+</sup>Closed period

|   |     |
|---|-----|
| Were the interests in the securities or contracts detailed above traded during a <sup>+</sup> closed period where prior written clearance was required? | No  |
| If so, was prior written clearance provided to allow the trade to proceed during this period?   | N/A |
| If prior written clearance was provided, on what date was this provided?  | N/A |

---

<sup>+</sup> See chapter 19 for defined terms.